3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
2
No longer available
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Expanded_access
2
Sponsor
Conditions
Myasthenic Syndromes, Congenital
2
Lambert-Eaton Myasthenic Syndrome
2
Nystagmus, Pathologic
1
Interventions
Amifampridine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Approved for marketing
×
Myasthenic Syndromes, Congenital
×
Amifampridine
×
Clear all
NCT02189720
2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT00872950
2022-04-11
LEMS
Lahey Clinic
Approved for marketing